Navigation Links
Thomson Reuters Examines Highly Cited Research in Bioterrorism
Date:5/18/2009

PHILADELPHIA and LONDON, May 18 /PRNewswire/ -- The Healthcare and Science business of Thomson Reuters today announced the results of a study assessing influential research in bioterrorism from 1999 to 2008. The findings appear in the May/June issue of Science Watch (www.sciencewatch.com) and are based on more than 12,000 bioterrorism-related papers published in Thomson Reuters-indexed journals during this time period.

Science Watch ranked the top 25 institutions by both total citations and citation impact (average citations per paper). The United States accounts for 23 of the top 25 institutions in both total citations and citation impact. The U. S. Army took the top spot in total citations with an impressive 9,637 citations to its researchers' work. The U. S. Centers for Disease Control and Prevention ranked second with 6,912 citations, and Johns Hopkins University with 5,006 citations ranked third.

U. S. institutions also led the pack in citation impact, a measure of average citations per published paper. The Institute for Genomic Research had an impact of 62.64 and the New York City Department of Health had an impact of 57.06. Claiming the third spot was the Imperial College of London with an impact of 31.55.

The most cited bioterrorism paper was published in 2001, regarding the causative agent of plague, Yersinia pestis; this paper has been cited nearly 500 times. The second most cited paper, entitled "Anthrax," was published two years before anthrax-tainted mail killed five people in 2001; this paper has now been cited more than 400 times. The third most-cited paper, published in 1999 and garnering more than 375 citations, discusses the use of smallpox as a biological weapon.

For the complete rankings of total citations and citation impact in the bioterrorism field, as well as a rundown of the most cited individual bioterrorism researchers during the time period, visit ScienceWatch.com.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Thomson Reuters Commemorates World IP Week with Series of Strategic Intellectual Property Seminars Across the U.S.
2. APS Healthcare and Thomson Reuters to Manage New York States Medicaid Clinical Best Practices Review Program
3. Thomson Reuters Names Hottest Researchers and Papers of 2007-2008
4. Despite Decline in Share of Global Output, U.S. Science Impact Still Strong, Says Thomson Reuters
5. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
6. The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results
7. Thomson Reuters Launches New Biomarkers Solution
8. Thomson Scientific Begins Expansion of Web of Science
9. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
10. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
11. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):